Research programme: vascular endothelial growth factor b - PhiloGene

Drug Profile

Research programme: vascular endothelial growth factor b - PhiloGene

Alternative Names: BiCentis; BiVastin; VEGFb

Latest Information Update: 22 Jun 2011

Price : $50

At a glance

  • Originator University of Bristol
  • Developer Alcon; PhiloGene
  • Class Cytokines
  • Mechanism of Action Vascular endothelial growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer; Retinal disorders

Most Recent Events

  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 23 Jul 2009 Vascular endothelial growth factor b licensed to Alcon
  • 23 Jul 2009 Preclinical trials in Retinal disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top